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Medulloblastoma is the most common malignant pediatric brain tumor (1). 
Medulloblastomas are formed in the cerebellum and have been resolved into four subtypes in 
humans: Sonic Hedgehog (SHH), WNT, group 3, and group 4. These designations have been 
developed using a variety of biological markers, including bulk transcriptomic and genetic 
analyses. However, within each of these 4 designations, clinical outcomes remain heterogeneous, 
suggesting that there are differences between tumors within a given subtype (2). Further 
stratification of each subtype is necessary in order to better tailor treatments and predict clinical 
outcomes.  
 The SHH subtype of medulloblastoma is driven by the aberrant proliferation of cells via 
the SHH pathway. The SHH signaling pathway is essential in the development of the central 
nervous system (3). Canonically, the pathway is activated when the glycoprotein Shh binds the 
transmembrane protein Patched1 (Ptch1) (fig.1). Ptch1 binds the G-protein coupled receptor-like 
protein Smoothened (Smo), however, binding of Shh dissociates Ptch1 from Smo relieving 
inhibition. Smo then accumulates at the primary cilium and initiates the signaling cascade. The 
cascade results in the translocation of the Gli2 transcription factor protein into the nucleus. Gli2 
upregulates the transcription of target genes including Ccnd1, Myc, and Gli1 resulting in a 
positive feedback loop and increased proliferation. In SHH medulloblastomas, tumor cells evade 
inhibition of the SHH pathway. 
 
Figure 1. The Sonic Hedgehog Pathway. Shh protein binds Ptch1 which releases Smo, leading to a signaling 
cascade that translocates Gli2 into the nucleus, upregulating transcription of Ccnd1, Gli1, and Myc and proliferation. 
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 Cerebellar granule neuron progenitors (CGNPs) have been identified as the proximal 
cells of origin for medulloblastomas in genetically-engineered mice (4). However, mouse studies 
have shown that aberrant hyperactivation of the SHH pathway in both more primitive neural 
stem cells of the Gfap lineage as well as in more committed CGNPs of the Math1 lineage results 
in the development of SHH medulloblastomas (5,6). Pathological and bulk transcriptomic 
analyses show these tumors to be similar to each other, but mice with tumors initiated in neural 
stem cells have a shorter survival time (5,6). In humans, it has been reported that age of onset is a 
predictor of clinical outcomes, again suggesting a role for developmental timing of tumor 
initiation in determining the malignancy of a tumor (2). These observations led us to hypothesize 
that the timing of tumor initiation plays a determining role in the cellular composition of 
medulloblastomas resulting in differential responses to treatment.  
 
Results  
Differential survival rate and response to radiation therapy between medulloblastomas from 
progenitors or stem cells 
To induce medulloblastoma formation, we bred SmoM2 mice, which contain a mutant 
Cre-dependent Smo gene that is constitutively expressed once activated (7), with Math1-Cre or 
hGfap-Cre mice that express Cre-recombinase in cells of the Math1 or Gfap lineage, 
respectively. The mutant Smo gene is not native to mice and therefore is not inhibited by the 
mouse Smo inhibitor protein Ptch1, resulting in constitutive activation of the SHH pathway. As 
Math1 is expressed in CGNPs, the Math1-Cre/SmoM2 (M-Smo) mice develop medulloblastomas 
with CGNPs as the cell of origin (8). In contrast, Gfap is expressed in central nervous system 
stem cells (9), leading hGfap-Cre/SmoM2 (G-Smo) mice to develop medulloblastomas with 
neural stem cells as the cell of origin. All M-Smo and G-Smo mice develop medulloblastomas. 
Although they both develop SHH-driven medulloblastomas, M-Smo mice live significantly 
longer than G-Smo mice without treatment (fig. 2a). Radiation therapy extends the survival time 
of M-Smo mice (fig. 2b) while radiation therapy has no observed effect on survival in G-Smo 
mice (fig. 2c).  
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Fig. 2 Survival analysis of M-Smo and G-Smo mice. a) Kaplan-Meyer curve of untreated M-Smo and G-Smo mice 
(p = 0.00003, log-rank test) b) Kaplan-Meyer curve of untreated M-Smo and radiation treated M-Smo mice (p = 
0.001) c) Kaplan-Meyer curve of untreated G-Smo and radiation treated G-Smo mice (p=0.275). P-values 
determined using log-rank test. 
Medulloblastomas from progenitors or stem cells exhibit differential cellular compositions 
We used single-cell RNA sequencing to identify differences between M-Smo and G-Smo 
medulloblastomas. We collected tumors at P15 from 5 M-Smo mice and 6 G-Smo mice and used 
the Drop-seq protocol to generate single cell transcriptomic profiles, collecting ~2,600 cells from 
each tumor (10, 11). We subjected the 11,984 M-Smo cells and 16,489 G-Smo cells to selection 
criteria as described in the Methods section in order to avoid keeping cells with insufficient read 
depths, cells that unintentionally have transcriptomic information from more than one cell, and 
premature lysis. After this filtering step, 5,930 M-Smo and 8,699 G-Smo were included in the 
analysis. As suggested by previous studies (12), to reduce batch effects in the analysis caused by 
different sequencing depths we randomly downsampled the G-Smo data by 60% to equate the 
sequencing depth to that of the M-Smo data. 
 We combined the M-Smo and G-Smo cells and used SCTransform to normalize the data 
and to identify the top 3,000 most variable genes. Following data normalization and variable 
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gene selection, we used principal component analysis (PCA) to identify 16 principle components 
(PCs) that explain >77% of the variance in the 3,000 variable genes. We then used Louvain 
clustering to identify 20 clusters that represent groupings of transcriptionally similar cells. We 
used Uniform Manifold Approximation and Projection (UMAP) to reduce the dimensionality of 
the data for graphical visualization. We color-coded the cells by their cluster designation in the 
UMAP projection (fig. 3a). We generated lists of genes that are differentially expressed in each 
cluster compared to all other clusters to determine the biological validity and cell type of each 














Fig. 3 Single-cell transcriptomic analysis of M-Smo and G-Smo tumors. a) UMAP projection of tumor cells from 
M-Smo and G-Smo mice color coded by clusters. b) Feature plot of stromal and neuronal markers. c) Feature plot of 
markers of CGNP development with an arrow indicating the axis of differentiation. d) Feature plot of stromal and 
neuronal markers separated by genotype. e) Fraction population of cells contributed by biological replicate to each 
cluster from M-Smo and G-Smo mice. * indicates p<.05 ** indicated p<.01 by Mann-Whitney U Test. f) Feature plot 
of Nes, Vim, Olig1, and Olig2 separated by genotype. 
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 Of the 20 clusters, we identified 8 clusters that are representative of tumor stroma using 
marker genes previously described (11,13-14). These stroma include astrocytes, 
oligodendrocytes, late oligodendrocytes, microglia/macrophages, fibroblasts, endothelial cells, 
neurons, and ciliated cells marked by expression of Aqp4, Sox10, Mog, C1qb, Col3a1, Pecam1, 
Meg3, and Rsph1, respectively (fig. 3b). The other clusters showed gene expression profiles 
mirroring those of CGNP development as described in (11), noting sequential expression of 
Mki67, Gli1, Barhl1, Cntn2, Grin2b, and Rbfox3 representing the developmental axis from a 
proliferative to a differentiated state (fig. 3c).  
 To better understand the differences between M-Smo and G-Smo tumor cells, we plotted 
M-Smo and G-Smo derived cells separately, noticing that M-Smo derived CGNP-like cells 
differentially populate the differentiated end of the developmental axis while G-Smo derived 
cells differentially populate the proliferative end (fig. 3d). To quantify this difference, we 
calculated the number of cells a biological replicate has assigned to a given cluster divided by the 
total number of cells of that replicate (fig. 3e). We found that cluster 0 on the proliferative end 
was significantly enriched for G-Smo cells (p = 0.0087, Wilcoxon rank-sum test) while cluster 12 
at the differentiated end is significantly enriched for M-Smo cells (p = 0.017). Cluster 10 is 
almost exclusively made up of G-Smo cells (p = 0.0043). In addition, there is an increased 
number of fibroblasts (p = 0.0087) and late oligodendrocytes (p = 0.0043) in M-Smo tumors. 
Together, these results show that M-Smo and G-Smo tumors have different cellular compositions, 
with M-Smo tumors having more differentiating cells than G-Smo tumors. 
 
Cell state differences between M-Smo and G-Smo tumors within CGNP-like population 
 To better understand the characteristics of the G-Smo cells in clusters 0 and 10, we 
generated differential expression lists between the G-Smo cells in each cluster and the M-Smo 
CGNP-like tumor clusters. We found that Olig family genes Olig1 and Olig2 are increased in 
both clusters as well as stem cell marker genes Nes and Vim (fig. 3f). In addition, we also note 
the upregulation of eukaryotic elongation factor genes Eef2, Eef1b2, and Eef1g and ribosomal 
protein genes in cluster 10, which suggests these cells have an increased capacity for protein 
synthesis (15). In contrast, all the cells in cluster 12 show higher expression of Gabra6 and Meg3 
when compared to all other cells in both tumor models, which are markers for differentiated 
cerebellar granule neurons (11, 16). G-Smo tumors are enriched for cells with stem cell 
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phenotypes and an elevated capacity for protein synthesis while M-Smo tumors are enriched for 
differentiated neurons. 
 
Stromal cell population differences between M-Smo and G-Smo tumors 
 To investigate the tumor microenvironment, we analyzed the stromal cells outside of the 
Gfap lineage, including macrophages/microglia and endothelial cells. In this analysis, we include 
cells from normal cerebellum collected at P7 to identify differences between tumor and normal 
stroma. We used the Harmony algorithm to combine the tumor and normal cerebellum datasets 
(17). We used the Harmony dimensional reduction to generate cell clusters and a UMAP 
projection as described previously. We identified stromal cells and neurons with the markers 
previously described (fig. 4a). We isolated the macrophage/microglia and endothelial cell 
clusters and subjected the cells to Harmony and clustering analysis. Following clustering, we 
generated differential gene lists for each cluster and quantified the contribution of each genotype 










































































Fig. 4 Single-cell transcriptomic analysis of of endothelial cells from M-Smo and G-Smo tumors combined 
with normal P7 cerebellum.  
a) Feature plot of stromal and neuronal markers for M-Smo and G-Smo mice and normal P7 cerebellum. b) 
Fraction population of cells contributed by biological replicate to macrophage/microglia each cluster from 
M-Smo and G-Smo mice and normal P7 cerebellum. * indicates p<.05 ** indicated p<.01 by Kruskal-
Wallis Test. c) UMAP projection of endothelial color coded by cluster and d) by genotype. Feature plots of 
e) general endothelial markers f) markers for cluster 0, and g) markers for cluster 1. 
 
 In the endothelial cell population, we identified 2 clusters (fig. 4b,c). Cluster 0 was 
common to both normal cerebellum and both tumor genotypes while cluster 1 was tumor-
specific (fig. 4b,d). All endothelial cell clusters expressed marker genes Cldn5 and Pecam1 (fig. 
4e). Cluster 0 showed upregulation of Mki67 and Apln, suggesting that these are proliferative, 
developing endothelial cells (22) (fig. 4f). In contrast, cluster 1 showed an upregulation of 
Abcb1a, Cxcl12, and Flt1, which have both been associated with medulloblastoma pathogenesis 
and tumor neoangiogenesis, respectively (23-24) (fig. 4g). Thus, M-Smo and G-Smo tumors have 
a unique endothelial cell population that is associated with pro-tumoral properties. Collectively, 
these results show that M-Smo and G-Smo tumors have differential stromal population 
































































Fig. 4 Single-cell transcriptomic analysis of of macrophage/microglia cells from M-Smo and G-Smo tumors 
combined with normal P7 cerebellum.  
a) UMAP projection of macrophage/microglial cells color coded by cluster. b) general macrophage/microglia 
marker. c) UMAP projection of macrophage/microglial cells color coded by genotype. d) Fraction population of 
cells contributed by biological replicate to macrophage/microglia each cluster from M-Smo and G-Smo mice and 
normal P7 cerebellum. * indicates p<.05 ** indicated p<.01 by Kruskal-Wallis Test. Feature plots of markers for e) 
cluster 0, f) cluster 1, g) cluster 2, and h) cluster 3. 
 
 In the macrophage/microglia population, we identified 4 clusters (fig. 5a). All 
macrophage/microglial clusters expressed the general marker C1qb (fig. 5b). Cluster 0 was 
common to both normal cerebellum and both tumor genotypes, cluster 1 was tumor-specific, and 
clusters 2 and 3 were common to M-Smo tumors and wildtype cerebellum (fig. 5c,d). Cluster 0 
was upregulated for Cx3cr1 and Sparc, which is a gene expressed by mature microglia (18). 
Cluster 1 showed upregulation for Mrc1, Igf1, and Wfdc17 (fig. 5e), suggesting that the cells 
comprising this cluster represent a mature M2-like macrophage population, which are thought to 
be immunosuppressive and tumorigenic (19). Cluster 2 was marked by higher expression of 
Ccr2, Cd74, H2-Ea, and Il1b indicating these are proinflammatory M1-like macrophages (20). 
Cluster 3 showed upregulation of Cd163 and Mrc1, suggesting these are also an M-2 like 
macrophage population (21). These results show that G-Smo and M-Smo tumors have a 
macrophage population that is unique to tumors in comparison to wildtype cerebellum and that 
M-Smo tumors have a more diverse set of macrophages than G-Smo tumors.  
 
Discussion 
Our results suggest that timing of tumor initiation results in markedly different tumors 
with regards to their malignancy and response to therapy. This finding was reified by their 
differential cellular composition as shown by single-cell RNA sequencing. The G-Smo 
medulloblastoma tumors initiated earlier in development led to shorter survival time and 
increased resistance to radiation. These tumors have a larger fraction of stem-like cells and 
Olig2+ cells. Cancer stem cells are important drivers of tumor progression (25), and Olig2+ cells 
have recently been shown to be enriched in therapy resistant and recurrent medulloblastomas 
(26), suggesting that these cells may be implicated in the worse clinical outcomes observed in G-
Smo tumors. In addition, we also found that there is a subset of G-Smo tumor cells that show an 
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upregulation of ribosomal protein genes and eukaryotic elongation factors, which has been 
implicated in promoting tumorigenesis in various cancers (15). In contrast, M-Smo 
medulloblastoma tumors initiated later in development were enriched in fully differentiated 
neurons that are nonpropagating and are therefore not contributing to tumor growth.  
 In addition to differences in the main tumor population, we observed differential tumor-
stromal interaction in the two tumor models as well as differences in stromal composition 
between the tumors and normal P7 cerebellum. M-Smo tumors proved to have a larger fraction of 
late oligodendrocytes and fibroblasts and to have a more diverse set of macrophage populations 
that are also present in normal cerebellum. M-Smo tumors have a unique M1-like macrophage 
population. M1 macrophages have been shown to have antitumor effects (21), suggesting that the 
M-Smo-specific population could be implicated in its reduced malignancy. We found that both 
tumors have a tumor-specific M2-like macrophage. As M2 macrophages are reported to have 
protumoral effects by suppressing the immune response (15), these macrophages may be an 
important population to target in the treatment of these tumors and further research should 
investigate their role in tumor progression. We also found a population of endothelial cells that is 
enriched in tumors. This endothelial population is marked by genes associated with 
medulloblastoma development and tumor growth (23). These tumor- and genotype-specific cell 
populations, along with the differentially enriched tumor cell populations, should be further 
studied with regards to their contribution to medulloblastoma growth and clinical outcomes so 
that targeted therapies can be developed against those populations implicated in increased tumor 
malignancy. Collectively, we have shown that the developmental timing of medulloblastoma 
initiation is an important predictor of tumor composition and clinical outcomes. 
 
Methods 
Mouse acquisition and Drop-seq protocol and data preprocessing of 5 M-Smo and 6 G-Smo 
tumors was conducted identically to the methods described in Ocasio et al. The code for the data 
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